LEF1 and non-small cell lung carcinoma: Yang et al. evaluated the in vivo metastatic efficacy of LEF1-AS1 in a mouse model, and more metastatic nodules were detected in the mice injected with LEF1-AS1-overexpressed A549 cells group compared with those of the control group, implying that LEF1-AS1 could serve as an oncogenic driver in the pathogenesis of NSCLC (Yang et al., 2019).